ASTRAZENECA WINS AUSTRALIA HIGH COURT APPEAL ON OMEPRAZOLE FORMULATION PATENT AstraZeneca today announced that the High Court of Australia has granted its appeal against an earlier Federal Court decision in a dispute with the generic pharmaceutical company, Alphapharm Pty Limited, about the validity of the formulation patent for omeprazole – the active substance used in Losec, a treatment for acid-related disorders, such as peptic ulcers.
ASTRAZENECA PLC – DIRECTORATE ANNOUNCEMENT AstraZeneca PLC today announced that Åke Stavling will be leaving the Company on 31 January 2003. Åke Stavling is 58 and has been an Executive Director since April 1999. He played a key role in the integration of Astra and Zeneca following the merger in 1999 and since then has been responsible for Business Development. From 1993-1999 he was Executive Vice President and Chief Financial Officer of Astra AB and before that held senior positions at Atlas Copco and Ericsson.
ASTRAZENECA REPORTS SIGNIFICANT PROGRESS ACROSS ITS PROMISING RESEARCH AND DEVELOPMENT PORTFOLIO AstraZeneca today updated analysts on the company's late stage development products and projects; the progress of earlier stage products, notably in the cardio-vascular and oncology therapeutic areas; and the improved productivity in drug discovery, at its annual business review meeting in Alderley Park, Cheshire, UK, a centre of excellence for Oncology Research and Development at AstraZeneca.
This website is intended for people seeking information on AstraZeneca's International business. We also have national business sites; links to these are under 'Other AZ websites' at the top of the page.